Antibodies against a synthetic peptide of the poliovirus replicase protein: reaction with native, virus-encoded proteins and inhibition of virus-specific polymerase activities in vitro by Baron, Margaret H. & Baltimore, David
JOURNAL OF VIROLOGY, Sept. 1982, p. 969-978
0022-538X/82/090969-10$02.00/0
Copyright 0 1982, American Society for Microbiology
Vol. 43, No. 3
Antibodies Against a Synthetic Peptide of the Poliovirus
Replicase Protein: Reaction with Native, Virus-Encoded
Proteins and Inhibition of Virus-Specific Polymerase Activities
In Vitro
MARGARET H. BARON AND DAVID BALTIMORE*
Center for Cancer Research and Department ofBiology, Massachusetts Institute of Technology, Cambridge,
Massachusetts 02139
Received 16 February 1982/Accepted 18 May 1982
A carboxy-terminal peptide of the poliovirus replicase protein (p63) was
chemically synthesized, coupled to bovine serum albumin carrier, and injected
into rabbits. The resulting antisera reacted with six virus-specific proteins from
HeLa cells infected with poliovirus: NCVP Ob, NCVP lb, NCVP 2, a protein of
about 60,000 daltons, p63, and NCVP 6b. The identity of the 60,000-dalton protein
is not known, but the other results were consistent with previous experimental
approaches which demonstrated that p63 and the other four polypeptides have
common coding sequences. An amino-terminal peptide of p63 failed to elicit an
immune response in rabbits. Antibodies raised against the p63 carboxy-terminal
peptide inhibited poliovirus replicase and polyuridylic acid polymerase activities
in vitro, providing strong support for earlier suggestions that these activities are a
property of a single virus-specific polypeptide.
The RNA-dependent RNA polymerase en-
coded by poliovirus is the only animal virus
replicase to have been isolated and purified in a
template-dependent form. Highly purified prep-
arations of poliovirus replicase are active in the
presence of poliovirion RNA and oligouridylic
acid [oligo(U)] (17, 22, 43), which acts as a
primer for RNA synthesis in vitro (M. H. Baron
and D. Baltimore, J. Biol. Chem., in press). The
requirement for oligo(U) can be replaced by
adding a protein fraction ("host factor") from
uninfected HeLa cells (17); this host factor is
found free in the cytoplasm (M. H. Baron and D.
Baltimore, J. Biol. Chem., in press). The RNA
product of either the oligo(U)- or host factor-
stimulated reaction is largely double-stranded in
character and a full-length copy of the positive-
strand RNA template, and represents the entire
viral genome (Baron and Baltimore, in press). In
the presence of host factor, the poliovirus repli-
case will also copy purified negative-strand
RNA to give full-length positive-strand RNA
(M. H. Baron, E. A. Scodeller, and D. Balti-
more, unpublished data). The replicase copuri-
fies with a polyadenylic acid [poly(A)]-oligo(U)-
dependent polyuridylic acid [poly(U)]
polymerase activity (16, 17, 20-22, 43). Both of
these activities are associated with the viral
protein p63 but not with noncapsid viral protein
(NCVP) 2, which is also present in many prepa-
rations of replicase-poly(U) polymerase (43).
To learn more about the poliovirus replication
proteins and their interrelationships, we sought
methods for the preparation of specific antibod-
ies against some of these viral gene products.
Highly purified preparations of poliovirus repli-
case contain only minute amounts of p63 and
NCVP 2 (unpublished data), although both pro-
teins are easily detected by radiolabeling. Direct
immunization of laboratory animals with the
authentic viral protein did not appear to be
feasible; therefore, we resorted to chemical syn-
thesis of p63 peptides.
It is now well established that antibodies
raised against peptides conjugated with macro-
molecular carriers may react not only with the
homologous peptides but also with the proteins
from which the peptides were originally isolated
(1-3, 5, 23, 30, 45). Even synthetic peptides,
when conjugated to a larger carrier polymer, can
be used to elicit the formation of antibodies
which are capable of reacting with the native
protein (4, 19). It should therefore be possible, at
least in principle, to prepare antibodies against
any protein for which the amino acid sequence is
available. By extension, the availability of a
nucleic acid sequence, from which the amino
acid sequence can be deduced, should and does
simplify matters further (29, 41, 44). Indeed, we
recently reported that antibodies raised against
the chemically synthesized genome-linked pro-
tein of poliovirus (VPg) react with native virus-
specific proteins (12).
The complete nucleotide sequence of the po-
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liovirus genome was recently reported (25, 34),
and the partial amino acid sequence determina-
tion was used to precisely map the amino termi-
nus of the replicase protein p63 (25, 38). NCVP
2, which contains the entire p63 sequence (25,
39), is the most 3'-proximal gene product (42);
this fact, taken together with the molecular
weight of p63 calculated from its mobility during
sodium dodecyl sulfate (SDS)-polyacrylamide
gel electrophoresis (21), indicates that the last
amino acid of p63 must virtually coincide with
the very end of the genomic coding region (25,
26, 34). We used solid-phase methods (11, 40) to
prepare a 13-residue amino-terminal peptide and
a 12-residue carboxy-terminal peptide [p63(N)
and p63(C), respectively]. Rabbits were immu-
nized with bovine serum albumin (BSA) conju-
gates of the peptides. Antibodies were success-
fully raised against p63(C) but not against
p63(N). Anti-p63(C) sera reacted with authentic
p63 as well as with NCVP Ob, NCVP lb, and
NCVP 2, each of which contains the entire p63
sequence (25, 39). Two other proteins, of ap-
proximate molecular weights 60,000 and 30,000,
were also recognized by the anti-p63(C) sera.
The identity of the larger polypeptide is un-
known, but the smaller protein is probably
NCVP 6b, believed to be an alternative cleavage
product of NCVP 2 (38).
Affinity-purified anti-p63(C) antibodies inhib-
ited both replicase and poly(U) polymerase in
vitro, supporting the earlier suggestion (21) that
the two enzymatic activities are a property of a
single protein.
MATERIALS AND METHODS
Materials. Na-Butyloxycarbonyl (tBoc)-L-amino
acid derivatives were purchased from Bachem Fine
Chemicals. [l4C]Nc-tBoc-L-alanine was prepared as
described previously (12).
['4C]N"-tBoc-L-leucine was prepared from
[U-14C]L-leucine (Amersham Corp.; 330 mCi/mmol)
and di-t-butyl-dicarbonate (Pierce) by a modification
of the procedures of Pozdnev (33) and Moroder et al.
(31), with a yield of 56% and a specific activity of 110
cpm/nmol.
Triethylamine, trifluoroacetic acid, and 3-mercap-
toethanol were redistilled and stored under nitrogen.
The sources of other reagents have already been
documented (12).
Amino acid coupling. Solid-phase peptide synthesis
was conducted by previously reported methods (11,
39), essentially as described by Baron and Baltimore
(12). Phenylalanine resin (5g) was used for the synthe-
sis of p63(N), and 10.7 g of resin was used for the
synthesis of p63(C). The synthesis of p63(C) was
complicated by the presence of tryptophan, which is
readily oxidized in the presence of trifluoroacetic acid.
Therefore, 1% (vol/vol) ,B-mercaptoethanol was added
to the trifluoroacetic acid-CH2Cl2, and acid treat-
ments were followed by three washes with 1% (vol/
vol) ,B-mercaptoethanol-CH2CI2 and then by three
washes with CH2CI2 alone.
Cleavage and deprotection. Peptide resins (2.5-g por-
tions) were cleaved in liquid HF-10% anisole at 0°C
for 1 h. After removal of excess HF under reduced
pressure, the peptide resin mixture was extracted
three times with ether to remove remaining anisole and
free amino acid side chain protecting groups, and the
peptide was extracted into glacial acetic acid and
lyophilized. Recovery (as monitored by liquid scintil-
lation counting of "C-labeled amino acid) was virtual-
ly quantitative.
Purification of the peptides. (i) Amino-terminal pep-
tide. Crude peptide recovered after cleavage of 2.5 g of
peptide resin was redissolved in 5.5 ml of 10%o acetic
acid and chromatographed on a 2.5- by 50-cm column
of Sephadex G-25 in 10%o acetic acid as described
previously (12). The peptide peak was divided into
three pools, each of which was subjected to amino acid
analysis. The central 87% of the peak was chosen for
further purification. One-half of the Sephadex G-25
pool II was lyophilized several times from distilled
water, redissolved in 4.5 ml of 0.1 M ammonium
formate (pH 3.1), and applied to a column (1.5 by 17
cm) of BioRad AG-50WX2 resin equilibrated with the
same buffer. After being washed with equilibration
buffer, the column was eluted with buffers of decreas-
ing ionic strength and increasing pH (ammonium for-
mate to pH 3.5; ammonium acetate thereafter). The
peptide eluted in 0.1 M ammonium acetate, pH 8.5.
The purified peptide was repeatedly lyophilized to
remove salt and stored frozen in water at a concentra-
tion of 32 mg/ml.
(ii) Carboxy-terminal peptide. Crude peptide was
again subjected to gel filtration on Sephadex G-25-
10% acetic acid, and the central 65% of the peptide
peak was used for further purification. This peptide
was only sparingly water-soluble above pH 5.5. A
portion (42%) of the Sephadex G-25 pool was adjusted
to 50 mM ammonium acetate (pH 5.5) and then applied
to a column (1.5 by 19 cm) of Biorex 70 equilibrated
with the same buffer. The column was eluted first with
ammonium acetate buffers of decreasing pH and then
with increasing amounts of acetic acid. The peptide
was recovered in 50% acetic acid and was lyophilized
repeatedly to decrease the concentration of acid. Be-
cause it was not soluble in water alone, the peptide
was stored as a powder at room temperature.
Amino acid analysis. Amino acid analyses were
performed by Erlinda Capuna in the laboratory of Lisa
Steiner, Massachusetts Institute of Technology (Table
1). The final recovery of purified amino-terminal pep-
tide, representing one-half of the Sephadex G-25 pool
II, was 89.8 mg (23.7%). The final recovery of car-
boxy-terminal peptide, representing 42% of the Sepha-
dex G-25 pool II, was 14.5 mg (10%).
Peptide analysis. Peptides were analyzed by high-
voltage paper electrophoresis and by silica thin-layer
chromatography in several solvents, as described in an
earlier report (12).
Conjugation of peptides with bovine serum albumin.
The amino-terminal peptide was coupled to BSA (Pen-
tex) with glutaraldehyde exactly as described previ-
ously (12). The efficiency of coupling was low (201%)
for reasons which are not clear. The carboxy-terminal
peptide could not be coupled under the usual condi-
tions because of solubility problems. The following
procedure was quite successful, with an unexpectedly
high coupling efficiency of 65.8%. The peptide was
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TABLE 1. Amino acid analysis of the synthetic
peptidesa
Synthetic Molar ratio
peptide Amino acid Theoretical Calculated"
p63(C) Arg 2 1.80
Asn 1 1.05
Thr 1 1.08
Ser 2 1.89
Leu 2 2.15
Tyr 2 2.14
Phe 1 0.96
Trp 1 1.18
p63(N) Asn 1 0.96
Thr 1 0.98
Ser 2 1.94
Glu 1 1.08
Pro 2 2.00
Ala 2 1.88
Leu 1 1.03
Phe 1 0.98
Lys 2 2.05
a See Fig. 1 for sequence.
b Molar ratio based on average of 12 residues for
p63(C) and 14 residues for p63(N).
suspended in 4 ml of 0.1 M sodium phosphate (pH
7.5)-50%o (vol/vol) methanol at 37°C. Approximately
90% of the material (5.2% Rmol) was soluble under
these conditions. BSA is not normally soluble in 509o
methanol; however, we were able to add the carrier
protein quickly and in concentrated form (0.1 ml of
BSA [50 mg/ml], 75 nmol, in 0.1 M sodium phosphate,
pH 7), followed by the addition of 15.2 RI of 2.5%
glutaraldehyde. The reaction proceeded at 37°C for 1
h, with no evidence of precipitation. Shortly after
transfer to a dialysis bag there was considerable pre-
cipitation, eventually resulting in a milky suspension.
The suspension was dialyzed against phosphate-buff-
ered saline for 2 days at room temperature and used
directly for immunization of rabbits.
Immunization. Two-month-old New Zealand White
rabbits were immunized with 420 ,g of conjugated
amino-terminal peptide or 240 Mlg of carboxy-terminal
peptide, emulsified in complete Freund adjuvant, by
intradermal injections at multiple sites. A sample of
serum was obtained from each animal before immuni-
zation. Tte animals were boosted with 240 ILg of
amino-terminal peptide or 120 p.g of carboxy-terminal
peptide in incomplete adjuvant, starting 4 weeks after
the priming immunization and repeated at 2- to 4-week
intervals thereafter. Antisera were drawn 7 to 10 days
after immunization, allowed to coagulate, clarified by
centrifugation at 20,000 x g for 15 min, adjusted to 2
mM phenylmethylsulfonyl fluoride-0.1% aprotinin,
and stored in aliquots at -20°C.
Antibodies against purified type 1 poliovirus were
prepared as described previously (12).
lodination of amino-terminal peptide. The amino-
terminal p63 peptide was iodinated by the procedure of
Bolton and Hunter (13).
Labeling of polovirus- and mock-infected HeLa cells.
The growth of HeLa cells in suspension in Joklik
modified Eagle medium with 5% horse serum and
infection by poliovirus were as described by Baltimore
et al. (9). Labeling of virus-infected cells in the pres-
ence of [35S]methionine and the subsequent prepara-
tion of cell lysates have already been described (12).
Mock-infected cell lysates were labeled with
[355]methionine as described by Baron and Baltimore
(12).
Nonspecific immunoprecipitation of capsid proteins
was prevented by pretreatment of total infected cell
lysates with anti-poliovirion type 1 serum, as de-
scribed previously (12).
Immunoprecipitation. Samples were diluted with 1%
Triton X-100-0.1% SDS-1% sodium deoxycholate-2
mM phenylmethylsulfonyl fluoride-0.1% aprotinin-
0.05% NaN3 in phosphate-buffered saline to a vol-
ume of 100 to 200 ,ul and incubated at room tempera-
ture for 60 min with 5 ,ul of anti-peptide serum or 5 p1
of preimmune serum unless otherwise indicated. Ad-
sorption of immune complexes by fixed Staphylococ-
cus aureus was performed as described previously
(12).
For competition experiments, lyophilized carboxy-
terminal peptide (insoluble in water) was suspended in
phosphate-buffered saline by vigorous mixing. Undis-
solved material was removed by centrifugation, and
the radioactivity in a small portion of the supernatant
was determined by liquid scintillation counting in 5 ml
of Bray cocktail. The specific activity of ["4C]leucine
in the final peptide (43 cpm/nmol) was used to calcu-
late the concentration of peptide in solution.
SDS-polyacrylamide gel electrophoresis. Samples
were analyzed by electrophoresis through 12.5% gels
containing 0.375 M Tris-hydrochloride (pH 8.9), 0.1%
SDS, and 0.1% N,N'-methylenebisacrylamide. The
stacking gel contained 4% acrylamide, 0.1% methy-
lenebisacrylamide, 0.125 M Tris-hydrochloride (pH
6.8), and 0.1% SDS. Electrophoresis was carried out
in 0.05 M Tris-0.384 M glycine-0.1% SDS at 120 V for
6 h. The gel was fixed for 1 to 2 h in 10%o (vol/vol)
methanol-10% (vol/vol) acetic acid, soaked for 1 h in
Enhance (New England Nuclear Corp.) and for 1 h in
water, and dried. An autoradiograph was prepared at
-70°C with Kodak XR-5 film and an intensifying
screen.
Stocks (30O, vol/vol) of acrylamide were purified as
described by Baron and Baltimore (12).
Coupling of p63(C) and BSA to Affigel. The p63
carboxy-terminal peptide was immobilized on an affin-
ity support by being coupled to Affigel 10 (N-hydroxy-
succinimide ester of cross-linked succinyl amino-bis-
ethylamino carboxymethyl agarose carboxamide;
BioRad Laboratories). The acidic protein BSA was
coupled to Affigel 15 (N-hydroxysuccinimide ester of
cross-linked succinyl methylimino-bis-propylamino
carboxymethyl agarose carboxamide). In preparation
for coupling to BSA, the agarose support was washed
on a sintered glass funnel with 3 volumes of isopro-
panol and 3 volumes of ice-cold distilled water. Protein
(400 mg) in 0.5 M HEPES (N-2-hydroxyethyl pipera-
zine-N'-2-ethanesulfonic acid)-KOH (pH 7.5) was rap-
idly combined with 22 ml of wet gel (the N-hydroxy-
succinimide has a very short half-life in aqueous
solution) and mixed at room temperature for 16 h. The
efficiency of coupling was 92.8%. Unreacted groups
on the agarose were blocked by reaction with 5
volumes of 1 M ethanolamine-hydrochloride (pH 8) for
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p63
p63(N)
74
I
p63(C)
p63 (C): Tyr - Ser -Thr - Leu -Tyr- Arg - Arg -Trp-()-Asp -Ser - Phe
450 461
p63 (N): Asn
-( Pro - Ser -Lys -Thr - Lys- Leu- Glu- Pro - Ser - Ala-Pheis 30
FIG. 1. Amino acid sequences of the synthetic p63 peptides. The p63 coding region is represented by the
horizontal line. (U) Positions within the sequence of the peptides chosen for synthesis. p63 is 461 amino acids in
length; p63(N) corresponds to residues 18 through 30, and p63(C) corresponds to residues 450 through 461.
Amino acids labeled with 14C are circled.
16 h at room temperature. The resin was washed twice
with alternate cycles of 0.2 M glycine-hydrochloride
(pH 2.7) and phosphate-buffered saline and then with 3
volumes of 50 mM Tris-hydrochloride (pH 7.5)-3 M
NaSCN; it was finally equilibrated with phosphate-
buffered saline. In preparation for coupling to the
carboxy-terminal peptide, Affigel 10 was washed with
3 volumes of dimethyl formamide, in which p63(C) is
highly soluble. (Affigel will couple in either aqueous or
organic solvents [15]). Sephadex G-25-purified peptide
(9.2 mg) in dimethyl formamide was mixed with about
4 ml of wet gel for 20 h at room temperature. The
efficiency of coupling was 75%. Unreacted groups on
the agarose were modified with ethanolamine and the
peptide-agarose was washed as described above.
Purification of sera by affinity chromatography. A
column (1.5 by 12.5 cm) of BSA-agarose was connect-
ed directly to a smaller column (1.0 by 2 cm) contain-
ing the p63(C) peptide-agarose. Immune sera (10 to 12
ml) were applied to the BSA-agarose. Phosphate-
buffered saline was used to wash unbound protein
through the first column and onto the affinity column.
The absorbance (280 nm) of eluted protein was mea-
sured by passing the eluate through a UVicord II
spectrophotometer (LKB Instruments). When protein
was no longer detectable in the eluate, the BSA-
agarose column was disconnected and the peptide-
agarose was washed with phosphate-buffered saline
containing 2 M KCI. Peptide-specific antibodies were
finally eluted with 50 mM Tris-hydrochloride (pH 7.5)-
3 mM NaSCN, concentrated 10-fold by precipitation
with 80%o ammonium sulfate, and dialyzed against 50
mM Tris-hydrochloride (pH 7.5)-50 mM KCl-0.1 mM
EDTA. The purpose of the BSA-agarose column was
to remove substances which might otherwise have
been adsorbed tightly but nonspecifically to the affini-
ty matrix and to remove antibodies raised against the
BSA used as carrier in the immunizations. The puri-
fied antibodies were tested for retention of biological
activity by immune precipitation of p63-containing
polypeptides from "S-labeled cell lysates.
The control antibodies used in these experiments
were raised in rabbits injected with a synthetic peptide
from Rous sarcoma virus, pp60$rc (peptide sequence,
Val-Cys-Lys-Val-Ala-Asp-Phe-Gly) and were a gener-
ous gift from Andrew Laudano, Massachusetts Insti-
tute of Technology. The antiserum was purified and
concentrated as described above.
Preparation of replicase and host factor. Replicase
was prepared from poliovirus-infected HeLa cells by a
modification of previously published procedures (16,
17) as detailed by Baron and Baltimore (in press). Host
factor was purified from a cytoplasmic supernatant
(130,000 x g) of uninfected HeLa cells by the proce-
dure of Baron and Baltimore (in press). Assay condi-
tions, detailed more explicitly in the appropriate figure
legends, were also those described by Baron and
Baltimore (in press).
RESULTS
Synthesis of peptides. Solid-phase methods
(11, 40) were used to synthesize an amino-
terminal, 13-residue p63 peptide comprising ami-
no acids 18 through 30 of the 461-amino acid p63
sequence, and a second p63 peptide comprising
the carboxy-terminal 12 amino acids [p63(N) and
p63(C), respectively]. The sequences corre-
spond to base numbers 6,038 through 6,076 and
7,334 through 7,369 (34) (Fig. 1). The molecular
weights of the peptides are 1,390 [p63(N)] and
1,607 [p63(C)].
The p63(C) sequence was chosen for synthesis
because of its terminal location in the polypep-
tide chain (see Walter et al. [44] for a discussion
of this approach). The p63(N) sequence was
chosen on the basis of its high content of polar
and charged amino acids; these residues, along
with the two prolines, are likely to be found on
the exterior surface of the protein and hence as
part of an antigenic determinant (6-8, 24, 36,
37).
Purified peptides were shown to be of the
correct composition by amino acid analysis (Ta-
ble 1). It should be noted, in particular, that the
molar yield of tryptophan in p63(C) (1.18 moll
mol of peptide) was in good agreement with the
theoretical value of unity, indicating that the
precautions taken to prevent oxidation of this
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amino acid were effective. Peptide purity was
further confirmed by thin-layer chromatography
and high-voltage paper electrophoresis as de-
scribed by Baron and Baltimore (12).
Antisera raised against the synthetic peptides.
The synthetic peptides were separately coupled
to BSA by reaction with glutaraldehyde. The
low solubility of p63(C) in aqueous solutions
above pH 5.5 precluded its coupling by the
conventional procedure, and 50%o methanol was
included in the buffer (see above for comments
on solubility of BSA under these conditions). A
radioisotopically labeled amino acid ([14C]ala-
nine for p63(N) and [14C]leucine for p63(C);
circled in Fig. 1) was incorporated into each
peptide during its synthesis so that the efficiency
of coupling could be monitored. Approximately
6 mol of p63(N) and 46 mol of p63(C) were
coupled per mole of protein carrier.
Rabbits were immunized with the BSA-p63
peptide conjugates. To determine whether an
antibody response to p63(N) had occurred, we
assayed for reaction of anti-p63(N) with
[125I]p63(N) labeled with the Bolton-Hunter rea-
gent. No precipitation of peptide by the sera
from immunized animals could be detected ei-
ther by direct counting of radioactivity in the S.
aureus pellets or by electrophoresis through
20% SDS-polyacrylamide gels followed by auto-
radiography (data not shown). The solubility
properties of p63(C) would have made iodination
with chloramine T or the Bolton-Hunter reagent
impracticable, and no attempt was made to label
this peptide with 1251. We therefore proceeded
immediately to immune precipitation from radio-
labeled lysates of virus-infected cells with the
anti-p63(C) serum.
Recognition of poliovirus-specific polypeptides
by the anti-peptide sera. To determine whether
authentic p63 as well as poliovirus-encoded
polypeptides containing p63-related sequences
could be identified in infected cells, we per-
formed immunoprecipitation experiments with
the anti-p63(C) sera. Tryptic peptide analysis
(results of Ambros, Flanegan, and Baltimore,
cited in reference 21) revealed the presence of
common sequences in p63 and the larger NCVP
2. A combination of protein and nucleic acid
sequence data were used to map p63, NCVP 2,
and the large replicase precursor NCVP lb on
the poliovirus genome (25, 39): p63 sequences
are contained within NCVP 2, which in turn is
contained within NCVP lb (Fig. 2). NCVP lb
constitutes the carboxy-terminal 55% (25) of
NCVP Ob, a single-cleavage product of the pro-
genitor poliovirus protein NCVP 00 (10). Be-
cause NCVP Ob is not normally detectable at all
in infected cells and because the level of NCVP
lb is rather low, poliovirus-infected cells were
labeled with [35Sjmethionine in the presence of
Zn2+; this metal inhibits many of the proteolytic
cleavages which give rise to mature viral gene
products (14) and thus allows large precursor
polypeptides to accumulate. Lysates frotn cells
infected in the presence or absence of ZnCl2
were examined by electrophoresis through and
autoradiography of 12.5% polyacrylamide gels.
It was clear that the ZnCl2 treatment had in-
creased the yield of high-molecular-weight vi-
rus-specific proteins (Fig. 3, lanes 1 and 6).
When the lysates were analyzed by immuno-
precipitation with anti-p63(C), five proteins la-
beled in the absence of ZnCl2 were recognized
by the immune sera but not the preimmune sera
(Fig. 3, lanes 2 and 3): NCVP lb (molecular
weight, 84,000 [25]); NCVP 2 (72,000 [25]); a
polypeptide of about 60,000 (tentatively termed
pre-p63); p63 (NCVP 4; 52,500 [25]); and NCVP
6b (approximate molecular weight, 30,000 [38]).
A sixth higher-molecular-weight protein was
specifically precipitated by anti-p63(C) from ex-
tracts of cells infected in the presence of ZnCl2
(Fig. 3, lanes 7 and 8); it appeared to be NCVP
Ob (149,000 [25]). NCVP Ob and NCVP lb were
also precipitated by antisera raised against VPg
peptides (12). Considerably more NCVP lb was
precipitated from lysates labeled in the presence
than in the absence of ZnCl2 (Fig. 3; compare
lanes 2 and 3 with lanes 7 and 8), reflecting its
increased abundance when proteolytic process-
ing was inhibited. Similarly, these same lysates
contained greatly reduced amounts of the lower-
Capsid proeis5' .Replication 3I
NCVP 00
00
0
O
Ob
lo 3b lb
I ,
Capsid proteins
preVPr3 2
Vt 7c_ p63(4)i - f
X 6a 6b
F , -'-
40
, ]
FIG. 2. Cleavage map of poliovirus gene products.
The relevant p63-related polypeptides are NCVP Ob,
NCVP lb, NCVP 2, and NCVP 6b. NCVP 6a and 6b
are shown in brackets because they are thought to be
alternative cleavage products of NCVP 2. Arrows
indicate the positions in p63 of the peptides chosen for
synthesis. NCVP lb undergoes proteolysis to VPg,
NCVP 7c, and p63; NCVP 7c is believed to be a
protease (32).
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terminal p63 peptide also failed to compete with
the proteins precipitated by antibody raised
against the carboxy-terminal peptide (data not
shown).
Antibodies raised against p63(C) precipitated
only p63 and NCVP 2 from highly purified,
enzymatically active preparations of replicase
labeled with [35S]methionine (data not shown).
This enzyme fraction contained large amounts of
labeled p63 and NCVP 2 and small amounts of
three or four 35S-labeled, lower-molecular-
weight proteins.
Mock-infected cell lysates were examined for
proteins cross-reactive with p63(C). An amount
of lysate was analyzed which was 100 times the
level necessary to heavily expose the X-ray film
(Fig. 4, lane 1). Twice as much anti-peptide
serum was incubated with this lysate as was
used for the experiments shown in Fig. 3. No
proteins were specifically precipitated by anti-
p63(C) (Fig. 4, lanes 2 and 3). Therefore, the
1 2 ::3
FIG. 3. Reaction with native poliovirus proteins by
antibodies raised against p63(C). Portions (0.5 ml) of
poliovirus-infected cell lysates labeled with [35S]me-
thionine in the presence or absence of ZnCI2 (0.8 mM)
were incubated for 1 h at room temperature with (lanes
2 and 7) 5 ,u1 of anti-p63(C) or (lanes 3 and 8) 5 p1d of
preimmune serum. Specific binding by anti-p63(C)
antibody to NCVP Ob, NCVP lb, NCVP 2, pre-p63,
p63, and NCVP 6b was completely inhibited in the
presence of 100 ,ug of p63(C) (lanes 4 and 9). Incuba-
tion with 100 ,ug of the insulin A chain (lanes 5 and 10)
did not interfere with recognition by anti-p63 of polio-
virus-specific proteins. Lanes 1 and 5 contain more
concentrated samples of total cell lysates and repre-
sent 1/20 the amount of material used for incubation
with antibody. Antigen-antibody complexes were col-
lected with S. aureus as described in the text and
subjected to electrophoresis through a 12.5% SDS-
polyacrylamide gel, which was then fixed and fluoro-
graphed.
molecular-weight viral proteins, which were
scarcely or not at all detectable in the immune
precipitates (Fig. 3, lanes 7 and 8).
The anti-p63(C) sera apparently recognized a
common antigenic determinant in proteins from
poliovirus-infected cell lysates and in the syn-
thetic peptide, because all six proteins were
specifically competed with when antibody was
incubated with radiolabeled infected-cell ex-
tracts in the presence of microgram amounts of
p63(C) (Fig. 3, lanes 4 and 9). The insulin A
chain at the same concentration did not compete
with any of the proteins recognized by anti-
p63(C) (Fig. 3, lanes 5 and 10): the amino-
'U
.a
FIG. 4. Incubation of anti-p63 with host cell pro-
teins. Lysates were prepared from mock-infected cells
labeled with [35S]methionine, and portions (1 ml) were
incubated with 10 p.1 of anti-p63(C) serum (lane 2) or
preimmune serum (lane 3) for 1 h at room temperature.
After a further 1 h of incubation (4°C) with 100 ,ul of
a 10% (vol/vol) suspension of S. aureus, the precipi-
tates were processed and subjected to electrophoresis
through a 12.5% SDS-polyacrylamide gel. Lane 1:
Sample of mock-infected cell lysate (1/100 the amount
of material used in the immunoprecipitations).
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FIG. 5. Inhibition of poliovirus polymerase activities by affinity-purified anti-p63(C). Approximately 0.3 ,ug
of replicase-poly(U) polymerase was incubated for 60 min at 0°C with the indicated number of ,uOD units (see the
text for definition) of anti-pp60&' (A) or anti-p63(C) (A). The appropriate components of the poly(U) polymerase
(panel A), host factor-stimulated replicase (panel B), or oligo(U)-stimulated replicase (panel C) reactions were
then added, and incubation was continued at 30°C for 30 min (A) or 60 min (B and C). The radioactivity
incorporated into acid-insoluble polymer was determined as described in the text. Each assay contained 20 ,uCi
of [a-32P]UTP (450 Ci/mmol). Fraction V host factor (1 Jl) was used for the experiment represented in panel B.
Oligo(U) was added to 30-fold molar excess (6 pmol) over template RNA (0.2 pmol) in the experiment shown in
panel C.
anti-p63(C) sera recognize a particular subset of
completely virus-specific proteins.
Consistent with their failure to precipitate
radiolabeled p63(N), sera from rabbits immu-
nized with the amino-terminal peptide did not
react specifically with any poliovirus-specific
proteins (data not shown).
Inhibition of replicase and poly(U) polymerase
activities by anti-p63(C). Poliovirus replicase and
poly(U) polymerase activities were nonspecifi-
cally inhibited by unpurified serum, and it was
therefore necessary to subject immune and con-
trol sera to affinity chromatography. The car-
boxy-terminal p63 peptide was coupled to Affi-
gel, an agarose derivative. Serum was first
applied to a large column of BSA-agarose (see
above) to remove antibodies raised against BSA
(with which the peptide had originally been
coupled before injection into rabbits) and other
proteins which might have bound tightly and
nonspecifically to the affinity column. Protein
which flowed through the BSA-agarose column
was conducted directly to a smaller affinity
column, to which anti-p63(C) antibodies then
bound.
Retention of specific antibody activity was
demonstrated by immunoprecipitation of p63
and p63-related polypeptides from labeled ly-
sates of infected cells (data not shown). Precipi-
tation of 125I-labeled peptide would have permit-
ted us to quantitate the recovery of activity; but,
for the reasons given above, the carboxy-termi-
nal peptide could not be labeled with iodine.
Antibodies raised against p63(C) specifically
inhibited not only poly(U) polymerase activity
(Fig. 5A) but also the host factor- and oligo(U)-
stimulated replicase reactions (Fig. 5B and C,
respectively). The controls used in early experi-
ments were preimmune sera which had been
subjected to the same chromatographic proce-
dures as the anti-p63(C) sera. These protein
fractions did not inhibit the poliovirus polymer-
ases (data not shown). Our concern that the
apparently specific inhibition by the purified
immune sera might be due instead to nonspecific
inhibition by immunoglobulin led us to the use of
an irrelevant antiserum as a control. Thus, anti-
serum from a rabbit immunized with a synthetic
peptide of the Rous sarcoma virus pp6Osrc was
purified by sequential chromatography on BSA-
agarose and pp60src-agarose under exactly the
same conditions as described for the p63(C)
antisera. Optical densities of the purified, con-
centrated antisera were measured at 280 nm
(OD280), and equal numbers of units (here ex-
pressed as LOD280 units) were added to parallel
polymerase assays. Anti-pp60('c had little effect
on either the poly(U) polymerase or the repli-
case-host factor reaction (Fig. 5A and B), but
stimulated the replicase reaction primed by oli-
go(U) (Fig. 5C), possibly by removing or mask-
ing some inhibitory substance. Anti-p63(C) in-
hibited all three reactions (Fig. 5A-C).
The antisera precipitated only p63 and NCVP
2 from radiolabeled preparations of replicase
(see above). Poly(U) polymerase and replicase
have always been found to copurify (16, 17, 22,
43), and the two activities have been shown to
be associated with p63 but not with NCVP 2
(43). Our immunological experiments therefore
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provide strong evidence that replicase and
poly(U) polymerase activities are properties of
the same virus-encoded polypeptide and that
this polypeptide must be p63.
DISCUSSION
The solutions to many problems in protein
biochemistry are greatly facilitated by the avail-
ability of specific antibodies. Our own interest in
the structure and function of the poliovirus
replicase has led us to the preparation of anti-
bodies against p63, the protein with which virus-
specific, RNA-dependent RNA polymerase ac-
tivity is associated (43). Highly purified
preparations of replicase contain such small
amounts of p63 that the simple immunization of
experimental animals is impracticable (a Coo-
massie blue-stainable polypeptide which comi-
grates with [35S]methionine-labeled p63 on
SDS-10% polyacrylamide gels is in fact a host
cell protein and can be resolved from p63 on a
7.5% gel; unpublished data). Therefore, we used
solid-phase methods to synthesize two peptides
of p63, one from the amino terminus and one
from the carboxy terminus (Fig. 1).
The amino terminus of p63 was pinpointed by
a combination of nucleic acid and protein se-
quencing methods (25, 39), revealing that the
coding region of p63 represents the carboxy-
terminal 70% of NCVP 2. NCVP 2 itself was
shown by pactamycin mapping to constitute the
most 3'-proximal of the viral gene products (42).
The molecular weight estimate (63,000) obtained
by gel electrophoresis (21) implies that the p63
carboxyl terminus must extend almost to the end
of genomic coding sequence, terminated by two
stop codons within 71 bases of the poly(A) tail
(25, 26, 34). The immunoprecipitation data pre-
sented here for anti-p63(C) (Fig. 3) provide clear
evidence for the assignment of the p63 carboxyl
terminus to the last stretch of translatable geno-
mic sequence (however, the molecular weight of
p63 is actually only about 53,000 [25]). They also
confirm the relationship between NCVP Ob,
NCVP lb, NCVP 2, and p63 (Fig. 2) and thus
support earlier conclusions drawn from other
types of experiments. Finally, they indicate that
the major open reading frame in the poliovirus
genome deduced by Kitamura et al. (25) and
Racaniello and Baltimore (34) must be correct.
Pulse-chase experiments suggested that there
existed two alternative sites for the cleavage of
NCVP 2 (or its precursor, NCVP lb), giving rise
either to NCVP 7c and p63 or else to NCVP 6a
and 6b (38) (Fig. 2). The specific precipitation of
NCVP 6b by anti-p63(C) sera confirms that this
protein is encoded within the 3' end of the
genome. It is not clear whether NCVP 6b is ever
generated directly from p63 itself. Thus far, no
enzymatic activity has been attributed to this
protein.
The identity of the 60,000-molecular-weight
polypeptide recognized by anti-p63(C) is un-
known. It is possible that the 60,000 protein was
precipitated as part of a complex with p63 or
other p63-related gene products, but its appear-
ance in the immune precipitates was reproduc-
ible, and the detergent composition of the phos-
pholysis buffer should not favor the formation of
aggregates or complexes. Nevertheless, this
protein was precipitated in only very small quan-
tities, and our designation of this protein as pre-
p63 must be considered tentative. Etchison and
Ehrenfeld (18) have also reported the existence
of a putative replicase protein precursor which
accumulates in poliovirus-infected cells in the
presence of a protease inhibitor (iodoacetamide)
and which has tryptic peptides in common with
the replicase protein. The two polypeptides de-
scribed by these workers (termed NCVP 4a and
4b) may correspond to our pre-p63 and p63,
respectively.
Interestingly, p63(N) failed to stimulate an
immune response in spite of the fact that it
seemed to be an ideal candidate for an antigen.
The non-immunogenicity of p63(N) may be the
result of immunological tolerance, possibly in-
volving a T cell-mediated suppression reaction.
It is also noteworthy that p63(C) successfully
induced the production of antibodies despite its
very poor solubility in water. This result sug-
gests that hydrophilicity is not a necessary con-
dition for the induction of an immune response
by a peptide antigen and is consistent with the
finding that some regions on the external surface
of a protein-where antigenic determinants
should reside (6-8, 24, 35)-are relatively hy-
drophobic (27, 28, 37).
A poly(U) polymerase activity has been found
to copurify with the poliovirus replicase (16, 17,
22, 43). These polymerase activities have fur-
thermore been shown to copurify with the viral
protein p63; NCVP 2 contains neither activity
(22, 43). The kinetics of appearance of poly(U)
polymerase (20) and replicase (16) activities in
the infected cell are very similar, suggesting that
the two enzymes are very closely related, at
least in function. The inhibition by anti-p63(C) of
both activities in highly purified enzyme frac-
tions provides strong evidence for the associa-
tion of these two polymerases with a single
protein and supports conclusions drawn on the
basis of protein purification alone.
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